阿卡波糖仿制药与原研药治疗2型糖尿病的临床综合评价Clinical Evaluation of Generic Acarbose and Original Drug in the Treatment of Type 2 Diabetes Mellitus
洪小媛;潘芸芸;陈吉生;
HONG Xiaoyuan;PAN Yunyun;CHEN Jisheng;The First Affiliated Hospital of Guangdong Pharmaceutical University;
摘要(Abstract):
目的系统评价阿卡波糖仿制药与原研药治疗2型糖尿病的临床综合价值,为临床治疗选择提供循证参考。方法计算机检索Pub Med、EMBase、Cochrane、CBM、CJFD、VIP和万方数据库。对符合纳入标准的RCT进行资料提取和质量评价后,运用Rev Man 5.3软件进行Meta分析。收集医药公司的药检报告、医院上报的不良反应和医院的销售情况,对比分析仿制与原研阿卡波糖的疗效、不良反应、质量及患者的可及性等。结果 Meta分析结果显示,阿卡波糖仿制药的疗效与原研药无差异,但不良反应发生率较低。随着国家集采项目推进,成本-效果比上将会趋同。结合真实世界信息,仿制药与原研药的质量指标、患者可获得性及可支付性无明显差异。结论阿卡波糖仿制药的疗效、药品质量及可及性与原研药相当,经济性将会趋同。两者都可作为2型糖尿病患者长期控制血糖的用药选择。
OBJECTIVE To systematically evaluate the clinical value of generic Acarbose and original drug in the treatment of type 2 diabetes,and to provide evidence-based reference for clinical treatment. METHODS Retrieval from Pub Med,EMBase,Cochrane library,CBM,CJFD,VIP and Wanfang Database. After quality evaluation and information extraction of RCT which met inclusion criteria,Rev Man 5.3 statistical software were used for Meta-analysis.To collect the acarbose test reports and,sales status from pharmaceutical companiesthe adverse reactions reports from hospitals,then compared and analyzed the quality,efficacy,adverse reactions and accessibility of patients between generic drugs and original drugs. RESULTS Results of Meta-analysis showed there were no significance between the efficacy of generic drugs and original drugs,while the incidence of adverse reactions of generic drugs was significantly lower. As the promotion of national centralized procurement projects,the ratio of cost and effectiveness would be identical. Refer to the reality information,there were no significant differences in quality,patient availability and affordability between the generic and the original drug. CONCLUSION Therapeutic efficacy,quality accessibility and affordability of generic acarbose are similar to those of original drug,the economy will be identical.The generic drug and the original drug can be used as the long-term blood glucose control drug choice for type 2 diabetes patients.
关键词(KeyWords):
2型糖尿病;阿卡波糖;仿制药;临床综合评价
type 2 diabetes mellitus;acarbose;generic drugs;clinical evaluation
基金项目(Foundation): 国家自然科学基金资助项目(81603526);; 广州市科技计划项目(201803010096)
作者(Author):
洪小媛;潘芸芸;陈吉生;
HONG Xiaoyuan;PAN Yunyun;CHEN Jisheng;The First Affiliated Hospital of Guangdong Pharmaceutical University;
Email:
DOI:
参考文献(References):
- [1]The Writing Team for the Diabetes Control and Complication Trial/Epidemiology of Diabetes Intervention and Complication Research Group.Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus[J].JAMA,2002,287(19):2563-2569.
- [2]Pinol C,Roze S,Valentine W,et al.Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain[J].Gaceta Sanitaria,2007,21(2):97-104.
- [3]Roze S,Valentine W,Evers T,et al.Acarbose in addition to existing treatments in patients with type 2 diabetes:health economic analysis in a German setting[J].Current medical research&opinion,2006,22(7):1415-1424.
- [4]国家食品药品监督管理总局.总局关于发布通过仿制药质量和疗效一致性评价药品的公告(第一批)[EB/OL].[2017-12-18].http://www.sfda.gov.cn/WS01/CL1756/220787.html.
- [5]Report of the Expert Committee on the Diagnosis and Classitication of Diabetes Mellitus[J].Diabetes Care,1997120(7):1183-1197.
- [6]叶山东.临床糖尿病[M].合肥:中国科学技术大学出版社,2017.
- [7]马捷,刘莹,钟来平,等.Jadad量表与Cochrane偏倚风险评估工具在随机对照试验质量评价中的应用与比较[J].中国口腔颌面外科杂志,2012,10(5):417-422.
- [8]陈平,李蓬秋,吕月婵,等.国产阿卡波糖与拜唐苹的临床疗效的比较[J].实用医院临床杂志,2005,2(1):50-51.
- [9]谌叶香,邓国锋,黄万育.阿卡波糖胶囊治疗2型糖尿病的临床观察[J].现代中西医结合杂志,2005,14(14):1861-1862.
- [10]胡泽富.国产阿卡波糖治疗2型糖尿病的药物经济学评价[J].广东药学,2005,15(6):42-44.
- [11]苗桂珍.阿卡波糖治疗2型糖尿病疗效观察[J].中国药师,2005,8(3):231-232.
- [12]冉兴无,张德翠,田浩明,等.国产阿卡波糖(胶囊剂)降糖疗效的多中心随机对照临床试验[J].四川大学学报:医学版,2007,38(6):1021-1024.
- [13]林甲宜,刘献华,张月霞,等.卡博平、拜唐苹干预对糖调节受损人群转归的影响[J].实用糖尿病杂志,2008,4(5):48-50.
- [14]金凤表,侯瑞田,刘晓艳,等.卡博平临床应用研究[J].现代预防医学,2008,35(5):970-973.
- [15]蔡小俐,黄璐,赵蓉,等.5种口服降糖药治疗2型糖尿病的药物经济学分析[J].中国药业,2009,18(13):40-41.
- [16]廖础欣.阿卡波糖治疗2型糖尿病的药物经济学评价[J].当代医学,2010,16(21):129-130.
- [17]简露.阿卡波糖胶囊剂与进口片剂的临床疗效比较[J].中国卫生产业,2012,9(1):83.
- [18]贺聃,陈俊.国产与进口阿卡波糖联合格列吡嗪治疗糖尿病疗效及成本分析[J].大家健康(学术版),2014,8(22):171-172.
- [19]李玉静.国产与进口阿卡波糖治疗2型糖尿病疗效及成本分析[J].山东医药,2014,54(26):76-77.
- [20]吴锡,张林.国产与进口阿卡波糖治疗2型糖尿病的药物经济学评价[J].河北医学,2014,20(11):1842-1845.
- [21]关东玲,谢灼骥,梁新林,等.口服卡博平与拜唐苹治疗2型糖尿病的疗效[J].广州医学院学报,2014,42(1):46-48.
- [22]孙莹.进口与国产阿卡波糖治疗2型糖尿病的效果与成本分析[J].吉林医学,2014.35(32):7126.
- [23]郑映红.国产与进口阿卡波糖治疗2型糖尿病的临床效果和成本[J].中国现代药物应用,2015,9(17):139-140.
- [24]朱蕾.阿卡波糖治疗2型糖尿病的成本效果分析[J].糖尿病新世界,2015,35(21):53-55.
- [25]常英霞.卡博平与拜糖平治疗2型糖尿病安全性比较[J].糖尿病新世界,2016,19(21):15-16.
- [26]曾燕.国产与进口阿卡波糖片治疗Ⅱ型糖尿病的系统评价[J].深圳中西医结合杂志,2016,26(16):138-139.
- [27]杨俊茹.阿卡波糖治疗2型糖尿病的药物经济学评价[J].中国医药指南,2017,15(11):161-162.
- [28]丁芝.国产与进口阿卡波糖治疗2型糖尿病应用的探讨[J].医药论坛志,2017,38(7):139-140.
- [29]余芸.阿卡波糖在2型糖尿病患者中的成本效果分析[J].心理医生,2017,23(9):129.
- [30]牛艳丽.阿卡波糖治疗2型糖尿病的药物经济学评价[J].中国医药指南,2018,16(12):76.
- [31]李晓峰.进口与国产阿卡波糖治疗2型糖尿病的疗效及经济性评价[J].医药前沿,2018,8(27):217-218.
- [32]王文涛.卡博平与拜糖平治疗2型糖尿病患者的效果对比[J].临床医药文献电子杂志,2018,5(A4):11-12.
- [33]陈长柱.阿卡波糖胶囊剂与进口片剂的临床疗效比较[J].中国农村卫生,2019,11(6):23.